Results from an ongoing clinical trial conducted at the National Cancer Institute's (NCI) Center for Cancer Research, has found that "many people with metastatic breast cancer can mount an immune reaction against their tumors." The clinical trial conducted on 42 women with metastatic breast cancer showed that 67% (28 of the 42 trial participants) had an immune response towards their cancer affliction. As such, the immune reaction approach was applied to treat 6 of the 28 women, "half of whom experienced measurable tumor shrinkage."
To read more about the results of this trial, click here.
Source mentioned: Zacharakis N, Lutfi LM, Seitter SJ, et al. Breast Cancers Are Immungenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. February 1, 2022. JCO. DOI: 10.1200/JCO.21.02170.
No comments:
Post a Comment